Corcept stock plunges 25% after Federal Circuit rules Teva's generic Korlym doesn't infringe patents. What it means for the $800M Cushing's drug franchise.

Corcept Therapeutics Crashes 25% After Federal Appeals Court Clears Teva Generic

Corcept's relacorilant extends ovarian cancer survival by 4.1 months in Phase 3 trial, cutting death risk 35%. FDA decision July 2026.

Corcept's Ovarian Cancer Drug Extends Lives by 4 Months in Pivotal Trial, Stock Whipsaws

Corcept Crashes 50% After FDA Rejects Relacorilant for Cushing's Syndrome

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Q3 2024

Q2 2024

Q1 2024

Q4 2023

Q3 2023

Q2 2023

CORCEPT THERAPEUTICS (CORT) Earnings Call Transcripts